Kernal Biologics
Kernal Biologics is a Cambridge, MA-based preclinical biotechnology company developing mRNA 2.0 therapeutics that combine AI-designed selective mRNA with antibody-decorated lipid nanoparticles to enable in vivo cell programming for cancer and autoimmune diseases.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kernal Biologics does
Kernal Biologics Inc. is a Cambridge, Massachusetts-based, development-stage private biotechnology company founded in 2018 that develops mRNA 2.0 therapeutics for cancer and autoimmune diseases. The company's core technology combines AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) to enable in vivo cell programming, eliminating the need for ex vivo manufacturing. The platform is anchored by kernaLM, a proprietary transformer-based large language model that predicts mRNA stability and translation efficiency, and supports two preclinical programs: KR-402, an in vivo CAR-T program for hematological malignancies and autoimmune disorders that achieves >90% in vivo delivery efficiency with T-cell-targeted LNPs, and KR-335, a solid-tumor program showing a 100x therapeutic index in preclinical models. Technology differentiators include two proprietary mRNA encryption designs that limit translation to cancer cells, extrahepatic LNP delivery that evades default liver accumulation, and an ML pipeline that mines clinical translatome datasets to identify cell-type-specific translation motifs.
The company's business model rests on two non-mutually-exclusive pillars: advancing its proprietary oncology and autoimmune pipeline toward clinical trials and IND filing, and licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharmaceutical and biotech partners for non-oncology applications. Kernal has secured strategic commercial validation through the Lilly Gateway Labs partnership (October 2025), technology ecosystem support via the NVIDIA Inception Program (August 2025), and up to $48 million in non-dilutive funding from ARPA-H (October 2025) for the KR-402 program. Total disclosed funding is approximately $81.5M from Hummingbird Ventures (lead), Amgen Ventures, Amino Collective, Civilization Ventures, Gaingels, HBM Genomics, HOF Capital, Y Combinator, and NASA. As of 2025, the company had 11-50 employees, no commercialized products, and no disclosed revenue.
Kernal Biologics firmographics
Firmographics- Name
- Kernal Biologics
- Legal name
- Kernal Biologics Inc.
- Website
- https://kernalbio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kernal Biologics is a Cambridge, MA-based preclinical biotechnology company developing mRNA 2.0 therapeutics that combine AI-designed selective mRNA with antibody-decorated lipid nanoparticles to enable in vivo cell programming for cancer and autoimmune diseases.
- Ownership category
- akta.pro rank
Kernal Biologics industry classification
Industry- Product category
- mRNA Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Kernal Biologics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kernal Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Licensing of non-oncology mRNA and LNP technology: Kernal Bio licenses its proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology applications such as infectious diseases, cardiovascular diseases, and metabolic disorders. This creates revenue to support internal oncology development programs.
- Clinical-stage therapeutic pipeline: The company is developing proprietary mRNA 2.0 therapeutics for cancer and autoimmune diseases (KR-335 for solid tumors, KR-402 for hematological malignancies). No commercial revenue yet as all programs remain in preclinical stage.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Kernal Biologics product offering
Product offeringCore offering
Kernal Biologics engineers human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Its mRNA 2.0 platform combines AI-designed, cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) that deliver mRNA to specific tissues (tumors, spleen, bone marrow, T cells) and ensure selective translation only in target cells. The company is advancing preclinical programs KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting), while licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharma/biotech partners for non-oncology applications.
Product overview
Kernal Biologics is a biotech company that has developed an mRNA 2.0 Platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for in vivo cell programming. The platform is anchored by kernaLM™, their proprietary large language model for mRNA design, and is supported by two clinical programs: KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting). The technology enables precise delivery of mRNA to specific cell types while ensuring selective translation only in target cells, eliminating off-target effects.
Differentiator
Problem solved
Functional benefit
Brands
- kernaLM™: Proprietary large language model (LLM) developed by Kernal Biologics for predicting mRNA stability and translation efficiency, introduced in June 2025.
- mRNA 2.0
Products and services
- mRNA 2.0 Platform Core technology platform combining AI-designed cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) for precise in vivo cell programming. Enables targeted delivery to specific tissues and cells (tumors, spleen, bone marrow, T cells) while ensuring selective translation in target cells, minimizing off-target effects. Foundation for all Kernal Bio pipeline programs and licensing activities.
- kernaLM™ Proprietary large language model (LLM) for mRNA design that predicts mRNA stability and translation efficiency. Built on transformer-based architecture, it processes genetic sequences, structural patterns, folding dynamics and multi-dimensional translatome data to computationally design selectively translated mRNA sequences for therapeutic applications.
- KR-402 In vivo CAR-T cell programming program targeting hematological malignancies (leukemia, lymphoma) and autoimmune disorders (multiple sclerosis, lupus). Uses T-cell-targeted antibody-decorated LNPs to deliver CAR mRNA for in situ CAR T programming without ex vivo manufacturing, achieving >90% in vivo delivery efficiency and effective B-cell depletion in preclinical models.
- KR-335 Solid tumor targeting program for cancers resistant to standard immunotherapies, including bladder cancer, Merkel cell carcinoma, gastric cancer, ovarian cancer, triple-negative breast cancer (TNBC), small cell lung carcinoma, cutaneous squamous cell carcinoma, and head and neck cancer. Shows 100x therapeutic index with strong efficacy and tolerability in preclinical models.
- T-cell-targeted LNPs Proprietary antibody-decorated lipid nanoparticles engineered to target T cells specifically. Evades default liver accumulation and achieves >90% in vivo delivery efficiency to T cells for targeted mRNA delivery, enabling in situ CAR-T programming.
- Extrahepatic LNP Delivery Technology Lipid nanoparticle delivery technology engineered to reach the right cells in the right tissue, overcoming the default liver accumulation typical of conventional LNPs. Reaches target sites including tumors, spleen, and bone marrow. Available for licensing to global pharma and biotech partners for non-oncology applications.
- Non-oncology mRNA and LNP Technology Licensing Out-licensing of Kernal Bio's proprietary non-immunogenic mRNA and extrahepatic lipid nanoparticle delivery technologies to global pharmaceutical and biotech companies for non-oncology therapeutic applications (infectious diseases, cardiovascular diseases, metabolic disorders). Generates licensing revenue to fund internal oncology pipeline development.
Quantifiable outcome
- >90% in vivo delivery efficiency with T-cell-targeted LNPs (KR-402 program)
- +3 more outcomes
Companies that use Kernal Biologics
Customer profileSegments3 records
Ideal customer profiles3 records
Kernal Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Kernal Biologics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Lilly Gateway LabscoreKernal Bio joined Lilly Gateway Labs in October 2025 to accelerate the development of in vivo cell therapies. Lilly Gateway Labs supports early-stage biotech companies with resources to advance their programs.
- NVIDIAcoreKernal Bio joined the NVIDIA Inception Program in August 2025. This provides access to NVIDIA's AI tools (RAPIDS, BioNeMo), GPU infrastructure, cloud resources, training, workshops, and a global network of AI startups and industry leaders. NVIDIA's computational resources will accelerate development of Kernal Bio's AI-driven mRNA design, including the kernaLM LLM.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Kernal Biologics competitors and assessment
Company assessmentBroad incumbents
- Moderna: Largest pure-play mRNA therapeutics company with a broad pipeline spanning infectious disease, oncology, and rare disease. Directly comparable to Kernal as a developer of mRNA-LNP therapeutics, but with far deeper clinical pipeline, manufacturing scale, and capital base.
- BioNTech: Global mRNA therapeutics leader with approved COVID vaccine and an expanding oncology pipeline including CAR-T programs (e.g., BNT211). Overlaps directly with Kernal on mRNA-LNP delivery and immuno-oncology, with substantially greater clinical and manufacturing resources.
Emerging players
- Strand Therapeutics: Synthetic biology company developing self-replicating and programmable mRNA therapeutics for oncology. Comparable to Kernal as an early-stage platform applying engineered mRNA logic to cancer, though Strand focuses on self-amplifying RNA rather than selective translation.
- Capstan Therapeutics: In vivo cell therapy company using LNP-delivered mRNA to engineer CAR-T cells inside the body, the same core mechanism as Kernal's KR-402. Most direct strategic comparator in the in vivo CAR-T space.
- Umoja Biopharma: Developer of in vivo CAR-T and related cell therapies using LNP and viral delivery platforms. Comparable to Kernal in pursuing in vivo reprogramming of immune cells, with overlapping hematological malignancy and autoimmune targets.
- Orbital Therapeutics: Flagship Pioneering-incubated RNA therapeutics company working on a broad RNA modality portfolio including mRNA, saRNA, and circular RNA. Comparable to Kernal as an AI-enabled, platform-based RNA therapeutics developer.
- Laronde (now part of Sail Biomedicines): Pioneer of engineered circular RNA (eRNA) for therapeutic protein expression. Comparable to Kernal as an emerging RNA therapeutics platform pursuing durable, programmable protein expression in vivo, though using a different RNA modality.
- Ascidian Therapeutics: Developer of RNA editing therapeutics targeting neurological and retinal diseases. Comparable to Kernal as an RNA-based therapeutic platform pursuing in vivo editing of disease-causing transcripts.
- Beam Therapeutics: Clinical-stage base editing company developing in vivo gene editing therapeutics using LNP delivery. Comparable to Kernal in pursuing targeted, in vivo nucleic acid delivery to specific tissues, though Beam edits DNA rather than expressing therapeutic proteins via mRNA.
- Verve Therapeutics: Clinical-stage in vivo gene editing company using LNP delivery to edit genes in the liver for cardiovascular disease. Comparable to Kernal in its focus on extrahepatic and liver-targeted LNP delivery, though Verve edits genomic DNA rather than delivering therapeutic mRNA.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Kernal Biologics social profiles
Digital presenceKernal Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kernal Biologics leadership team
Management profileNumber of profiles
Profiles17 records
Kernal Biologics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kernal Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kernal Biologics
What does Kernal Biologics do?
Kernal Biologics engineers human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Its mRNA 2.0 platform combines AI-designed, cell-selective mRNA with proprietary antibody-decorated lipid nanoparticles (LNPs) that deliver mRNA to specific tissues (tumors, spleen, bone marrow, T cells) and ensure selective translation only in target cells. The company is advancing preclinical programs KR-402 (in vivo CAR-T for hematological malignancies and autoimmune disorders) and KR-335 (solid tumor targeting), while licensing its non-immunogenic mRNA and extrahepatic LNP delivery technology to global pharma/biotech partners for non-oncology applications.
Is Kernal Biologics a public or private company?
Kernal Biologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kernal Biologics founded?
Kernal Biologics was founded in 2018. It employs 11 to 50 people.
Where is Kernal Biologics based?
Kernal Biologics is headquartered in Cambridge, United States, in the North America region.
How does Kernal Biologics make money?
Two revenue lines are on record. Licensing of non-oncology mRNA and LNP technology is the primary driver. The others are clinical-stage therapeutic pipeline.
Who are Kernal Biologics's main competitors?
Broad incumbents on record are Moderna and BioNTech. Emerging players are Strand Therapeutics, Capstan Therapeutics, Umoja Biopharma, Orbital Therapeutics, Laronde (now part of Sail Biomedicines), Ascidian Therapeutics, Beam Therapeutics and Verve Therapeutics.
Does Kernal Biologics have an API?
No public API is recorded for Kernal Biologics.
What industry is Kernal Biologics in?
Kernal Biologics's product category is mRNA Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.